DYADIC INTERNATIONAL INC
DYAI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DYAI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DYAI
Dyadic International Inc. is a biotechnology company focused on developing and commercializing its proprietary C1 and Dapibus™ microbial protein production platforms for use in human and animal biopharmaceuticals and non-pharmaceutical products.
Key risk: Limited cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for DYADIC INTERNATIONAL INC.
Dyadic International Inc. is a biotechnology company focused on developing and commercializing its proprietary C1 and Dapibus™ microbial protein production platforms for use in human and animal biopharmaceuticals and non-pharmaceutical products.
- Dyadic's proprietary C1 and Dapibus™ platforms are designed to produce stable, properly folded proteins for vaccines, monoclonal antibodies, and other biologics [sec_mda · as of 2025-05-14].
- The company completed a Phase 1 first-in-human study in 2024 for a vaccine antigen produced using its C1 platform, demonstrating safety for human applications [sec_mda · as of 2025-05-14].
- As of June 30, 2026, Dyadic reported cash and equivalents of $3.0M, total revenue of $1.0M, and a net loss of -$2.1M [sec].
- Dyadic expects its existing cash, cash equivalents, restricted cash, and investment securities (totaling approximately $6.6 million as of March 31, 2026) to fund operations for at least the next twelve months [sec_mda · as of 2026-05-13].
- The company faces significant uncertainty regarding its ability to raise additional capital and achieve commercial milestones, with an accumulated deficit and negative shareholders' equity [sec_mda · as of 2026-03-25].
What works
- Dyadic's C1 platform has been validated for human use through a successful Phase 1 first-in-human study in 2024, demonstrating safety for vaccine antigen production [sec_mda · as of 2025-05-14].
- The company's platforms (C1 and Dapibus™) are versatile, targeting both human and animal health biopharmaceuticals as well as non-pharmaceutical biologic products, potentially broadening commercial opportunities [sec_mda · as of 2025-05-14].
- Dyadic has secured fully funded biopharmaceutical projects and extensive animal studies, indicating some external validation and collaboration interest [sec_mda · as of 2025-05-14].
What to weigh
- Dyadic has a history of net losses and negative shareholders' equity (-$0.5M as of June 30, 2026), indicating ongoing financial challenges [sec].
- The company's cash position ($3.0M as of June 30, 2026) is limited, and it may need substantial additional capital to fund future development and operations [sec_mda · as of 2026-03-25].
- Clinical development risks are high; the company acknowledges that even promising early-stage results may not lead to successful later-stage trials or regulatory approval [sec_mda · as of 2026-03-25].
- Dyadic faces intense competition from alternative technologies that may not require microbial or cell-produced proteins, potentially reducing market adoption of its platforms [sec_mda · as of 2026-03-25].
From the filings
Quoted directly from source documents.
Dyadic's C1 platform demonstrated safety in a Phase 1 human study.
“in 2024, the successful completion of a Phase 1 first-in-human study for a vaccine antigen produced using C1, which demonstrated its safety for human applications”
SEC MD&A · May 14, 2025
Dyadic expects existing cash to fund operations for at least 12 months from March 31, 2026.
“The Company expects its existing cash, cash equivalents, restricted cash and its investment securities, including accrued interest, totaling approximately $6.6 million as of March 31, 2026, will be sufficient to meet its operational, business, and other liquidity requirements for at least the next twelve (12) months”
SEC MD&A · May 13, 2026
Dyadic's platforms target both pharmaceutical and non-pharmaceutical products.
“antibodies, vaccines, and metabolites or other non-pharmaceutical biologic products”
SEC MD&A · March 25, 2026
Dyadic may need substantial additional capital.
“We may need substantial additional capital in the future to fund our business.”
SEC MD&A · March 25, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $3.0M as of June 30, 2026, may be insufficient if operating plans change or additional capital is not raised [sec].
- Clinical and regulatory uncertainty — Early-stage clinical results may not predict future success; no assurance of regulatory approval for any product candidate [sec_mda · as of 2026-03-25].
- Competitive technology risk — Alternative technologies may not require microbial or cell-produced proteins, potentially reducing demand for Dyadic's platforms [sec_mda · as of 2026-03-25].
- Dependence on collaborations — Revenue generation depends on license agreements, milestones, and royalties from collaborators, which are uncertain [sec_mda · as of 2026-03-25].
What to watch
- Dyadic's ability to raise additional capital through equity offerings, collaborations, or other means, given its limited cash position [sec_mda · as of 2026-05-13].
- Progress of clinical development for product candidates using the C1 and Dapibus™ platforms, particularly any later-stage trials [sec_mda · as of 2026-03-25].
- Execution of the company's rebranding and R&D strategy to enhance platform adoption and generate commercial milestones [sec_mda · as of 2026-03-25].
- Any new collaboration or licensing agreements that could provide non-dilutive funding or validate the platforms [sec_mda · as of 2025-05-14].
Sources: SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run DYADIC INTERNATIONAL INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available DYADIC INTERNATIONAL INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
8.4 months
OCF -$2M · Net income -$2M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 3 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
36
Total value held
$4.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,856,466 | $1.5M |
| chapin davis, inc. | 888,004 | $728K |
| truist financial corp | 326,200 | $267K |
| geode capital management, llc | 313,508 | $257K |
| blackrock, inc. | 275,425 | $226K |
| vanguard fiduciary trust co | 139,478 | $114K |
| marathon capital management | 110,000 | $90K |
| sage mountain advisors llc | 106,564 | $87K |
| landscape capital management, l.l.c. | 97,016 | $80K |
| renaissance technologies llc | 81,665 | $67K |
Showing top 10 of 36 institutional holders of DYADIC INTERNATIONAL INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 0.5%
- Days to cover
- 1.2
- Shares short
- 130,008
- Daily short volume (Jun 12, 2026)
- 33.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DYAI short interestGovernance
Frequently asked questions
What is the AI investment thesis for DYADIC INTERNATIONAL INC?
Dyadic International Inc. is a biotechnology company focused on developing and commercializing its proprietary C1 and Dapibus™ microbial protein production platforms for use in human and animal biopharmaceuticals and non-pharmaceutical products.
Who is the CEO of DYADIC INTERNATIONAL INC?
Mr. Mark A. Emalfarb is the chief executive officer of DYADIC INTERNATIONAL INC (DYAI).
Where is DYADIC INTERNATIONAL INC headquartered?
DYADIC INTERNATIONAL INC (DYAI) is headquartered in Jupiter, FL, United States.
What therapeutic areas does DYADIC INTERNATIONAL INC focus on?
DYADIC INTERNATIONAL INC develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.